Impact of Advanced Hybrid Closed Loop on Youth With High-Risk Type 1 Diabetes Using Multiple Daily Injections

Overview

Journal Diabetes Care

Specialty Endocrinology

Date 2023 Jan 23

PMID 36689621

Authors

Alisa Boucsein

Antony S Watson

Carla M Frewen

Olivia J Sanders

Jillian J Haszard

Shirley D Jones

Philippa J Milford-Hughes

Martin I de Bock

Benjamin J Wheeler

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate glycemic outcomes in youth (aged 13-25 years) with type 1 diabetes and high-risk glycemic control (HbA1c ≥8.5% [69 mmol/mol]) on multiple daily injection (MDI) therapy after transitioning to advanced hybrid closed loop (AHCL) therapy.

Research Design And Methods: This prospective, 3-month, single-arm, dual-center study enrolled 20 participants, and all completed the study.

Results: HbA1c decreased from 10.5 ± 2.1% (91.2 ± 22.8 mmol/mol) at baseline to 7.6 ± 1.1% (59.7 ± 11.9 mmol/mol), and time spent in target range 70-180 mg/dL (3.9-10.0 mmol/L) increased from 27.6 ± 13.2% at baseline to 66.5 ± 9.8% after 3 months of AHCL. Two episodes of diabetic ketoacidosis attributed to infusion set failure occurred.

Conclusions: AHCL has the potential to improve suboptimal glycemia in youth with type 1 diabetes previously on MDI therapy.

Citing Articles

Predictors of glycaemic improvement in children and young adults with type 1 diabetes and very elevated HbA1c using the MiniMed 780G system.

Zhou Y, Boucsein A, Michaels V, Gray M, Jefferies C, Wiltshire E Diabetes Obes Metab. 2025; 27(4):2138-2146.

PMID: 39831344 PMC: 11885095. DOI: 10.1111/dom.16210.

Parental perspectives following the implementation of advanced hybrid closed-loop therapy in children and adolescents with type 1 diabetes and elevated glycaemia.

Lai S, Styles S, Boucsein A, Zhou Y, Michaels V, Jefferies C Diabet Med. 2024; 42(3):e15448.

PMID: 39587412 PMC: 11823305. DOI: 10.1111/dme.15448.

Simplified meal announcement study (SMASH) using hybrid closed-loop insulin delivery in youth and young adults with type 1 diabetes: a randomised controlled two-centre crossover trial.

Laesser C, Piazza C, Schorno N, Nick F, Kastrati L, Zueger T Diabetologia. 2024; 68(2):295-307.

PMID: 39560745 PMC: 11732900. DOI: 10.1007/s00125-024-06319-w.

Children and adolescent with suboptimal control of type 1 diabetes improve during the first 2 years on automated insulin delivery system.

Kiilavuori M, Varimo T, Tuomaala A, Pulkkinen M Diabetes Obes Metab. 2024; 27(1):134-142.

PMID: 39344828 PMC: 11618217. DOI: 10.1111/dom.15992.

Protocol for a prospective, multicenter, parallel-group, open-label randomized controlled trial comparing standard care with Closed lOoP In chiLdren and yOuth with Type 1 diabetes and high-risk glycemic control: the CO-PILOT trial.

Boucsein A, Zhou Y, Haszard J, Jefferies C, Wiltshire E, Styles S J Diabetes Metab Disord. 2024; 23(1):1397-1407.

PMID: 38932805 PMC: 11196497. DOI: 10.1007/s40200-024-01397-4.